














Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
NU578 Unit 1 Study NotesNU578 Unit 1 Study Notes
Typology: Study Guides, Projects, Research
1 / 22
This page cannot be seen from the preview
Don't miss anything!















1. Difference between adverse effects, side effects and toxicity Adverse drug reaction - ADR (adverse drug reaction)- any noxious, unintended, and undesired effect that occurs at normal drug doses - Adverse reactions can range in intensity from mildly annoying to life threatening - When drugs are used properly, many ADRs can be avoided, or at least minimized. - 3 possible outcomes of when drugs interact ▪ One drug may intensify effects of other (potentiative interaction) ▪ One drug may reduce the effects of the other (inhibitory interaction) ▪ Combination may produce a new response not seen with either drug alone - Anticipating ADRs can help minimize them - Nurses and patients should know the major ADRs that a drug can produce - In severe illness increased risk of ADR - Adverse events are most common in older adults and the very young. (Patients older than 65 years account for more than 50% of all ADR cases.) Side effect - A nearly unavoidable secondary drug effect produced at therapeutic doses - Ex: drowsiness caused by traditional antihistamines, gastric irritation caused by aspirin - Generally predictable, intensity is dose dependent. - May develop soon after drug use starts or may not appear until a drug has been taken for weeks or months - There is no such thing as a wholly selective drug: all drugs can cause side effects - Can be disturbing if they occur without warning. Ex: rifampin (tuberculosis) imparts a harmless red-orange color to urine, sweat, saliva, and tears. Your patient will appreciate knowing about this in advance. Toxicity - The degree of detrimental physiologic effects caused by excessive drug dosing - Ex: Overdose of morphine coma, overdose of insulin severe hypoglycemia - Know early signs and procedure - Toxicity has come to mean any severe ADR, regardless of the dose that caused it o Anticancer drug in therapeutic doses neutropenia high risk of infection 2. Controlled substances—what are the schedules and how are they set? For instance, is a CS2 drug more or less addicting than a CS3 drug? Controlled substances - CSA- principal federal legislation addressing drug abuse - Schedule I, II, III, IV, or V
o Schedule I: high potential for abuse and no approved medical use in the United States o Schedules II through V all have approved applications, based on abuse potential and potential for causing physical or psychologic dependence o Of the drugs that have medical applications, those in Schedule II have the highest potential for abuse and dependence ▪ Drugs in the remaining schedules have decreasing abuse and dependence liabilities
- CS2 is more addicting than a CS 3. How do drugs cross membranes? What things influence this—what do polarity and charge (ionization) have to do with drugs crossing membranes (or not crossing them)? - drugs must cross membranes to leave the vascular system and reach their sites of action - drugs must cross membranes to undergo metabolism and excretion Three Ways to Cross a Cell Membrane
disease states affecting other organs, and pathways involved in the way the drug distributes through the body, such as first-pass metabolism.
8. What are characteristics of agonists and antagonists? Partial agonists? Chapter 5 Page 49- 51 Agonists are molecules that activate receptors. Exposure to an agonist wound cause the cell to become less responsive or desensitized. Drugs that mimic the body’s own regulatory molecules are agonist. Antagonists produce their effects by preventing receptor activation by endogenous regulatory molecules and drugs. The body does not produce antagonists as a response to a medication. Partial agonists are an agonist that has only moderate intrinsic activity. As a result, the maximal effect that a partial agonist can produce is lower than that of a full agonist. Partial agonist is interesting in that they can act as antagonists as well as agonists. 9. What is the advantage of a drug with a high therapeutic index? Chapter 5 page 53 High therapeutic index (large or wide) indicates that a drug is relatively safe. Conversely, a small (low or narrow) therapeutic index indicates that a drug is relatively unsafe. A patient would have to take a much higher dose of such a drug to reach the toxic threshold than the dose taken to elicit the therapeutic effect. A ratio that compares the blood concentration at which a drug becomes toxic and the concentration at which the drug is effective. The larger the therapeutic index (TI), the safer the drug is. 10. What is P-glycoprotein and how can it influence drug-drug interactions? P.26& 34 (10th^ edition) P-Glycoprotein (PGP) is a transmembrane protein that transports a wide variety of drugs OUT of the cells. This transporter is present in many sites, including the liver, kidney, placenta, intestine, and capillaries of the brain. Like P450 isoenzymes, PGP is subject to induction and inhibition by drugs. In fact, most of the drugs that induce or inhibit P450 have the same effect on PGP. Drugs that induce PGP can have the following effects on other drugs:
a. CYP2C9 variants increase toxicity (bleeding) from warfarin (variant CYP2D9 metabolize warfarin too slowly allowing it to accumulate in the body) i. FDA recommends testing for variant, but can also just monitor INR (cheaper) b. Thiopurine methyltransferase (TPMT) activity can be decreased by variant gene codes, causing delayed metabolic deactivation of 2 thiopurine anticancer drugs (thioguanine and mercaptopurine [Purinethol]. Increased levels can fatally damage bone marrow. i. FDA recommends testing for TPMT variant and give reduced dose c. 1 % of US population produces a form of dihydropyrimidine dehydrogenase that poorly metabolizes fluorouracil (treats cancer). Toxic levels can cause death from CNS injury. Genetic variants that alter DRUG TARGETS: Alter STRUCTURE of drug receptors and other target molecules Affected targets on normal cells: a. Beta1-adrenergic receptor (ADRB1) that are hyperresponsive to activation i. Activation – exaggerated increase in hypertension ii. Blockade – exaggerated decrease in blood pressure iii. Usually European ancestry- beta blockers work better for light skinned b. Warfarin works by inhibiting vitamin K epoxide reductase complex 1 (VKORC1) i. Variant VKORC1 can be easily inhibited (anticoagulation is achieved at lower levels of warfarin) Normal doses can cause excessive bleeding. ii. FDA recommends testing for variant VKORC Affected targets on cancer cells and viruses: a. Human epidermal growth factor receptor type 2 (HER2) protein is a receptor for hormones that stimulate tumor growth. It is over expressed in 25% of breast cancer patients and indicates poor prognosis but also better response from trastuzmab (Herceptin) – works only against tumors that overexpress HER i. FDA requires + test for HER2 overexpression b. Cetuximab (Erbitux) for metastatic colorectal cancer works only against tumors that express the epidermal growth factor receptor (EGHR) i. FDA requires evidence of EGFR expression to use drug c. Maraviroc (Selzentry) for HIV infection works by binding with viral surface protein chemokine receptor 5 (CCR5). CCR5 binds to strains of HIV that are CCR5 tropic to enter immune cells. Maraviroc only works on CCR5 tropic strains of HIV. i. FDA requires testing to confirm CCR5 tropic HIV infection Genetic variants that alter IMMUNE RESPONSE to drugs: Increases risk of severe hypersensitivity reactions a. Carbamazepine (Tegretol, Carbatrol) for epilepsy and bipolar disorder
ii. FDA recommends screening for HLA-B1502 in Asians before use b. Adacavir (Ziagen) for HIV infections- potentially fatal hypersensitivity reactions in patients with HLA-B i. FDA recommends screening for variant gene before use
the delay
22. Make sure you know the basics of the receptor types and subtypes in the peripheral nervous system (alpha 1 and 2, beta 1 and 2, dopamine, cholingergic). Chapter 13 (Physiology of the Peripheral Nervous System) p 109-117 (10th^ edition book) There are 2 basic categories of receptors located with the PNS: cholinergic and adrenergic. Cholinergic mediate responses to acetylcholine. Adrenergic mediate responses to epinephrine and norepinephrine. Cholinergic receptors have 3 subtypes: nicotinic N, nicotinic M, and muscarinic. Adrenergic receptors have 4 subtypes: alpha 1, alpha 2, beta 1, and beta 2. Dopamine receptors are classified as adrenergic, these receptors do not respond to epinephrine or norepinephrine; they only respond to dopamine, a neurotransmitter found primarily in the CNS. Cholinergic receptor subtypes : Activation of nicotinic N (neuronal) receptors promote ganglionic transmission at all ganglia of the sympathetic and parasympathetic nervous systems. These receptors release epinephrine from the adrenal medulla. Activation of nicotinic M (muscle) receptors cause contraction of skeletal muscle. Activation of muscarinic receptors (located in target organs of parasympathetic nervous system) elicits an appropriate response from the organ involved. Causing increased glandular secretions, contraction of smooth muscle in the bronchi and GI tract, slowing heart rate, contraction of the sphincter muscle of the iris causing miosis, contraction of the ciliary muscle of the eye causing the lens to focus for near vision, dilation of blood vessels, and voiding of the urinary bladder. Muscarinic cholinergic receptors are not associated with the nervous system in any way. It is not clear how they active physiologically; drugs are able to active these receptors and cause vasodilation which can cause blood pressure to fall. Adrenergic receptor subtypes: Alpha 1 receptors are located in the eyes, blood vessels, male sex organs, prostatic capsule, and bladder. Ocular alpha 1 receptors activation leads to mydriasis (dilation of the pupil). Activation of alpha 1 receptors in the blood vessels produces vasoconstriction. Activation of alpha 1 receptors in the sexual apparatus of males causes ejaculation. Activation in the bladder causes contraction. Alpha 2 receptors are located on nerve terminals. These receptors are referred to as presynaptic or prejunctional. The function of these is to regulate transmitter release. Alpha 2 receptors are also present in the CNS. Beta 1 receptors are located in the heart and kidney. Activation of these causes increases in heart rate, force of contraction, and velocity of impulse conduction through the atrioventricular node. Activation in the kidney causes release of renin into the blood; this helps elevate blood pressure. Beta 2 receptors in the lung leads to bronchial dilation. Activation in the uterus causes relaxation of uterine smooth muscle. Activation in the arterioles of the heart, lungs, and skeletal
muscles cause vasodilation. Activation in the liver and skeletal muscle promotes glycogenolysis (breakdown of glycogen into glucose) which increases blood glucose levels. Activation in skeletal muscles causes contraction. The only dopamine receptors of clinical significance are located in the vasculature of the kidney. Activation dilates renal blood vessels, enhancing renal perfusion.
23. What are drugs like bethanechol, cevimeline, atropine, Ditropan, scopolamine, etc. used for? To which receptors do they bind? Major SE? Chapter 14 (Muscarinic Agonist and Antagonists) Bethanechol is a cholinergic drug, a muscarinic agonist. The drug binds reversibly to muscarinic cholinergic receptors to cause activation. It has little to no effect on nicotinic receptors. It is used for oral administration. It crosses membranes poorly. This drug is only approved for urinary retention. It has been used off label to treat GERD. Side effects of this drug are relatively rare. It can cause hypotension and bradycardia, excessive salivation, increased secretion of gastric acid, abdominal cramps, and diarrhea. It may cause bronchoconstriction; it is contraindicated for patients with asthma. It is contraindicated for patients with hyperthyroidism; it may increase heart rate and cause an arrhythmia. (p 120 10 th edition) Cevimeline is a derivative of acetylcholine with actions much like those of bethanechol. The drug is indicated for relief of xerostomia (dry mouth) in patients with Sjogren’s syndrome. This drug relieves dry mouth by activating muscarinic receptors on residual healthy tissue in salivary glands, promoting salivation. This drug has also been used to manage keratoconjuctivitis sicca (dryness of cornea and conjunctiva, AKA dry eyes). It increases tear production. It may cause excessive sweating, nausea, rhinitis, and diarrhea, blurred vision. It is contraindicated in patients with uncontrolled asthma, chronic bronchitis, COPD, narrow-angle glaucoma, and iritis (p 121 10th^ edition) Atropine is a muscarinic antagonist. All responses to atropine result from preventing receptor activation by endogenous acetylcholine. At therapeutic doses, atropine produces selective blockade of muscarinic cholinergic receptors; if dosage is sufficiently high, the drug will produce some blockade of nicotinic receptors too. This effects heart, exocrine glands, smooth muscles and eyes. Toxic doses can cause hallucinations and delirium, extremely high doses can result in coma, respiratory arrest, and death. It can be used to treat peptic ulcer disease, asthma, and biliary colic. Xerostomia, blurred vision and photophobia, elevation of intraocular pressure, urinary retention, constipation, anhidrosis (deficiency of sweat), tachycardia, asthma exacerbation are some effects of using Atropine. (p122-124 10 th^ edition) Ditropan (Oxybutynin) is an anticholinergic agent that is a M3 muscarinic subtype; these receptors are most widely distributed, being found in salivary glands, the bladder detrusor, GI smooth muscle and eyes. M3 selective blockers can cause constipation, blurred vision and photophobia, dry eyes, and some degrees of dry mouth. It will NOT cause tachycardia or
· (Nondepolarizing) Pancuronium · (Depolarizing) Succinylcholine · Administered IV..works by blocking the effects of acetylcholine at nicotinicm receptors at the neuromuscular junction causing muscle relaxation. Commonly used with general anesthesia to aid in intubation and to maintain skeletal muscle relaxation during surgical procedures. · Monitor: perception of pain (patient can be fully alert, but unable to communicate, respiratory arrest (monitor vitals until muscle function fully recovers- keep artificial ventilation available for immediate use), hypotension (due to significant amounts of histamine release), Electrolyte disturbance (low potassium enhances paralysis---high potassium reduces paralysis), Malignant hyperthermia (elevated body temp high as 43degrees C, cardiac dysrthythmias, unstable blood pressure, metabolic acidosis, muscle rigidity)
26. How is anaphylaxis treated (Lehne pg. 152 & 845) · The drug of choice to treat anaphylaxis is Epinephrine (catecholamine) · Epinephrine can be given IV or IM, subQ, intraspinal, inhalation, topical. Injections available solutions 0.1mg/mL and 1mg/mL · Works by activating alpha1 (increase cardiac output-increase blood pressure, promotes vasoconstriction, beta1, and beta2 (counteract bronchoconstriction) · Adverse Effects : hypertensive crisis, dysrhythmias, angina pectoris, necrosis, hyperglycemia · Adrenergic Agonists : Epinephrine, adrenalin · Bete-Delective Adrenergic Agonists -Isoproterenol (Isuprel) Anaphylactic shock is a syndrome characterized by bronchoconstriction, hypotension, and edema of the glottis. Histamine plays a minor role in anaphylaxis, and are of little help as treatment options. · H1 antagonists (classic antihistamines) treat allergic disorders, motion sickness, insomnia…first generation (highly sedating) examples: Diphenhydramine, Promethazine, Hydroxyzine (see table 70.1 pg. 847 Lehne) second generation examples: Certirizine, Loratadine.
Alpha-Adrenergic Antagonists: Pharmacokinetic Properties Drug Route^ Peak^ Half-Life Metaboli sma Excretion Uses Tamsulosin PO 4–5 hr (with food) 6–7 hr (without food) 9–15 hrc^ Hepatic, urine(primary) and feces BPH only Terazosin PO 1–2 hr 9–12 hrc^ Hepatic, bile (primary) and urine HTN and BPH Tables of Drugs are on pages 161 & 162
Beta-Adrenergic Antagonists: Pharmacokinetics and Pharmacologic Properties Generic Name ISA Lipid Solubility Peak Half-Life (Adults) Metabolism Excretion FIRST-GENERATION: NONSELECTIVE BETA BLOCKERS Nadolol 0 Low 3–4 hr 20–24 hr Not metabolized Urine (unchanged drug) Pindolol ++
Moderate 1 hr 3–4 hr Hepatic Urine Propranolol 0 High 1–4 hr 3–5 hr Hepatic Urine Sotalol 0 High 2.5–4 hr 12 hr None Urine (unchanged drug) Timolol 0 Low 1–2 hr 4 hr Hepatic Urine SECOND-GENERATION: CARDIOSELECTIVE BETA BLOCKERS Acebutolol + Moderate 2–4 hr Drug: 3–4 hr Metabolite: 8– hr Feces (primary), urine Atenolol 0 Low 2–4 hr 6–9 hr Hepatic Feces (primary), urine Betaxolol 0 Low 1.5–6 hr 14–22 hr Hepatic Urine Bisoprolol 0 Moderate 2–4 hr 9–12 hr Hepatic Urine Esmolol 0 Low 1–2 min Drug: 9 min Metabolite: 3– hr Red cell esterases Urine Metoprolol 0 High IV: 20 min PO: 1–2 hr 3–7 hr Hepatic Urine THIRD-GENERATION: BETA BLOCKERS WITH VASODILATING ACTIONS Carvedilol 0 Moderate 1–2 hr 5–11 hr Hepatic Feces (primary), urine